Security key
78397T202
SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS)
CUSIP: 78397T202
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 123,835
- Total 13F value
- $482,911
- Share change
- -82,381
- SEC-reported price per share
- $3.90
- Number of holders
- 2
- Value change
- -$321,286
- Number of sells
- 1
- Shares outstanding
- 76,568,369
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
2
Top holders
2
SABS full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
SAB Biotherapeutics, Inc. SEC filings
SAB Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 78397T202
Recent filing periods:
Ownership snapshot
Top reported holders of SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Caligan Partners LP
Disclosed value leader
Vivo Opportunity Fund Hol...
Comparable rows
15/15
Latest evidence
24 Apr 2026
13D/G
13F
Lead comparable stake: 10%
13D/G row: Caligan Partners LP
Showing 1-6 of 15 holder rows.
Quick read
Caligan Partners LP leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Caligan Partners LP's linked filing trail.
Comparable ownership
Top 5
Caligan Partners LP
10%
Vivo Opportunity Fund Holdings, L.P.
10%
BALYASNY ASSET MANAGEMENT L.P.
10%
RA CAPITAL MANAGEMENT, L.P.
9.9%
Commodore Capital LP
9.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Caligan Partners LP |
13D/G
13F
JOHNSON DAVID EDWARD · Company
|
10%
|
$31,072,107
7,967,207 shares
|
$0 | 31 Mar 2026 |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
10%
|
$54,973,720
25,931,000 shares
|
$0 | 29 Sep 2025 |
| BALYASNY ASSET MANAGEMENT L.P. |
13D/G
13F
Company
|
10%
|
$19,850,762
5,089,939 shares
|
$0 | 31 Mar 2026 |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
Company
|
9.9%
|
$30,195,359
7,311,225 shares
|
+$8,858,028 | 19 Mar 2026 |
| Commodore Capital LP |
13F
13D/G
Company
|
9.9%
from 13D/G
|
$16,857,745
4,401,500 shares
|
— | 31 Mar 2026 |
| Woodline Partners LP |
13D/G
13F
Company
|
9.9%
|
$14,323,021
7,125,881 shares
|
$0 | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
123,835
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
75
Q2 2026 holders
2
Holder diff
-73
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend